{"groups":[{"description":"A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.","id":"FG000","title":"Bortezomib, Dexamethasone, Rituximab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Symptomatic patients with Waldenstrom's requiring therapy, previously untreated.","recruitmentDetails":"Outpatient clinic at DFCI"}